Comparative Pharmacology
Head-to-head clinical analysis: MINOXIDIL EXTRA STRENGTH FOR MEN versus TRANSDERM NITRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINOXIDIL EXTRA STRENGTH FOR MEN versus TRANSDERM NITRO.
MINOXIDIL EXTRA STRENGTH (FOR MEN) vs TRANSDERM-NITRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
Nitroglycerin is converted to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
Topical: 1 mL of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 mL (100 mg).
Initial dose 0.2-0.4 mg/hour transdermally once daily. Titrate to 0.4-0.8 mg/hour. Maximum 0.8 mg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing.
Terminal elimination half-life is approximately 1-4 minutes after IV administration due to rapid metabolism. After transdermal application, the apparent half-life is 3-4 hours due to continued absorption from the skin depot, resulting in a prolonged clinical effect.
Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%).
Renal (primarily) and biliary; ~60-80% of the dose is excreted renally as metabolites, with <1% unchanged. Fecal excretion accounts for ~10-20%.
Category A/B
Category C
Vasodilator / Hair Growth Stimulant
Vasodilator